ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 2456

Associations of Toll-like Receptor (TLR)-4 Single Nucleotide Polymorphisms and Rheumatoid Arthritis Disease Progression

Marshall Davis1, Tricia LeVan2, Fang Yu3, Harlan Sayles4, Jeremy Sokolove5, William H. Robinson6, Kaleb Michaud7, Geoffrey M Thiele8 and Ted R. Mikuls4, 1Internal Medicine, University of Nebraska Medical Center, Omaha, NE, 2Univ of Nebraska Med Ctr, Omaha, NE, 3University of Nebraska Medical Center, Omaha, NE, 4Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, 5VA Palo Alto Healthcare System and Stanford University, Palo Alto, CA, 6VA Palo Alto Health Care System and Stanford University, Palo Alto, CA, 7National Data Bank for Rheumatic Diseases, Wichita, KS, 8Omaha VA and the University of Nebraska Medical Center, Omaha, NE

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: ACPA, Disease Activity, polymorphism, rheumatoid arthritis (RA) and toll-like receptors

  • Tweet
  • Email
  • Print
Session Information

Session Title: Rheumatoid Arthritis - Human Etiology and Pathogenesis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Toll-like receptor (TLR)-4 signaling pathways have been implicated in both the innate and adaptive immune responses that characterize rheumatoid arthritis (RA).  In this study, we examined the associations between TLR-4 single nucleotide polymorphisms (SNPs) and RA using a large well-characterized RA cohort.  

Methods:

A total of 1,559 patients were genotyped for three TLR4 SNPs (rs1927911, rs11536878, and rs4986790), which were selected using a haplotype tagging strategy. Measures of disease severity included the Disease Activity Score-28 (DAS28), Multidimensional Health Assessment Questionnaire (MD-HAQ), Clinical Disease Activity Index (CDAI), and Simplified Diseases Activity Index (SDAI). Associations of TLR4 SNPs with these measures were examined longitudinally (mean of 10 visits, range: 0-60) using generalized estimating equations in both univariate and multivariate analyses, adjusting for age, sex, race, comorbidity, body mass index, smoking, erythrocyte sedimentation rate (ESR), rheumatoid factor (RF) and anti-CCP positivity, methotrexate and anti-tumor necrosis factor use. Based on existing data showing that anti-citrullinated protein antibody (ACPA)-containing immune complexes may drive TLR4 signaling in RA, analyses were also stratified by ACPA positivity including antibody positivity to anti-CCP and anti-citrullinated fibrinogen (cFb) antibody.

Results:

RA patients homozygous for the minor allele of TLR4 rs1927911 demonstrated lower disease activity over follow-up including lower DAS28 (p<0.001), CDAI (p=0.002), and SDAI (p=0.010) in univariate analysis and lower DAS28 (p<0.001) and CDAI (p=0.007) in multivariate analysis (Table). Disease activity among those homozygous for the minor allele tended to be numerically lower in groups with elevated anti-CCP and anti-cFb antibody though no significant differences by ACPA status were identified.  There were no associations of TLR4 rs11536878 and rs4986790 SNPs with any of the RA disease activity measures.

Conclusion:

We found TLR4 rs1927911 genotypes are associated with the rate of disease progression over time independent of other factors. Although further studies are needed to identify mechanisms by which variation in rs1927911 impacts inflammatory burden, these data are consistent with reports in other disease states suggesting that this SNP is associated with a meaningful anti-inflammatory effect and support the concept of TLR4 as a potential therapeutic target in RA.

Univariate Analysis

Multivariate Analysis

DAS28

DAS28

Genotype

Beta-Coef

95% CI

P-Value

Beta-Coef

95% CI

P-Value

CC

Ref.

—-

—-

Ref.

—-

—-

CT

-0.010

-0.022, 0.003

0.130

-0.016

-0.030, -0.003

0.019

TT

-0.038

-0.056, -0.020

<0.001

-0.029

-0.047, -0.012

<0.001

MD-HAQ

MD-HAQ

Beta-Coef

95% CI

P-Value

Beta-Coef

95% CI

P-Value

CC

Ref.

—-

—-

Ref.

—-

—-

CT

0.002

-0.004, 0.009

0.472

0.001

-0.005, 0.007

0.755

TT

-0.007

-0.015, 0.001

0.102

-0.006

-0.015, 0.002

0.154

CDAI

CDAI

Beta-Coef

95% CI

P-Value

Beta-Coef

95% CI

P-Value

CC

Ref.

—-

—-

Ref.

—-

—-

CT

-0.065

-0.185, 0.056

0.292

-0.125

-0.293, 0.043

0.145

TT

-0.250

-0.408, -0.091

0.002

-0.274

-0.472, -0.076

0.007

SDAI

SDAI

Beta-Coef

95% CI

P-Value

Beta-Coef

95% CI

P-Value

CC

Ref.

—-

—-

Ref.

—-

—-

CT

-0.075

-0.203, 0.052

0.248

-0.116

-0.284, 0.053

0.178

TT

-0.232

-0.410, -0.054

0.010

-0.247

-0.453, -0.041

0.019

Table:  Associations of TLR-4 rs1927911 genotype with RA disease progression (DAS28, HAQ, CDAI, and SDAI differences per year of follow up); p-values < 0.0167 (Bonferroni correction) considered to be statistically significant


Disclosure:

M. Davis,
None;

T. LeVan,
None;

F. Yu,
None;

H. Sayles,
None;

J. Sokolove,
None;

W. H. Robinson,

Atreca, Inc.,

5;

K. Michaud,
None;

G. M. Thiele,
None;

T. R. Mikuls,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/associations-of-toll-like-receptor-tlr-4-single-nucleotide-polymorphisms-and-rheumatoid-arthritis-disease-progression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2022 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies